EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

Abstract Background The ATLANTIC trial reported that higher PD-L1 expression in tumors was involved in a higher objective response in patients with EGFR + /ALK + non-small cell lung cancer (NSCLC), indicating the possibility of anti-PD-1/PD-L1 therapy as a third-line (or later) treatment for advance...

Full description

Bibliographic Details
Main Authors: Shunli Peng, Rong Wang, Xiaojuan Zhang, Yueyun Ma, Longhui Zhong, Ke Li, Akihiro Nishiyama, Sachiko Arai, Seiji Yano, Wei Wang
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Molecular Cancer
Subjects:
PD-L1
EGFR-TKIs resistance
Signaling pathways
Lung cancer
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s12943-019-1073-4

Internet

http://link.springer.com/article/10.1186/s12943-019-1073-4

Similar Items